Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 30 April 2018

Indication(s)

Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content

Journal articles

Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

Objectives: To assess the efficacy and safety of combined aclidinium bromide and long-acting beta2-agonists in stable COPD.

Added 11 days ago

Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use.

Introduction: For patients with chronic obstructive pulmonary disease (COPD), one of the main goals in its management is to reduce the number of disease exacerbations. Roflumilast is an anti-inflammatory compound...

Added 12 days ago

Inspiratory muscle training improves autonomic modulation and exercise tolerance in chronic obstructive pulmonary disease subjects: A randomized-controlled trial.

Objectives: We aimed to evaluate the effect a regular inspiratory muscle training program on autonomic modulation measured by heart rate variability, exercise capacity and respiratory function in chronic obstructive pulmonary...

Added 12 days ago

When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.

While single-inhaler triple therapy (SITT) devices were not available when the Global Initiative for Chronic Obstructive Lung Disease strategy and National Institute for Health and Care Excellence guidelines were developed...

Added 12 days ago

Women and COPD: do we need more evidence?

The increasingly female face of chronic obstructive pulmonary disease (COPD) prevalence among women has equalled that of men since 2008, due in part to increased tobacco use among women worldwide and exposure to...

Added 26 days ago

Load more

View all 13128 Journal articles items
Guidelines

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD.

Freshly updated for 2017, the latest edition of the Global Strategy document is the premiere evidence-based reference tool for the implementation of effective disease management plans, and represents the current best practices...

Added 1 year ago

An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation

The purpose of this Statement is to update the 2006 document, including a new definition of pulmonary rehabilitation and highlighting key concepts and major advances in the field.

Added 5 years ago

Load more

View all 1443 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/001179
Orphan designation No
Date First Approved 05-07-2010
Type Medicinal product subject to medical prescription
Marketing authorisation holder AstraZeneca AB
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions